[{"id":"89fea682-b243-4d0a-b33b-68ffee2754d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05144698","created_at":"2021-12-03T17:53:38.066Z","updated_at":"2024-07-02T16:35:51.936Z","phase":"Phase 1/2","brief_title":"RAPA-201 Therapy of Solid Tumors","source_id_and_acronym":"NCT05144698","lead_sponsor":"Rapa Therapeutics LLC","biomarkers":" EGFR • ALK • BRCA","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation","tags":["EGFR • ALK • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-03-30"}]